Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Williams VSL, Wakeford ME. The predictive validity of the National Teacher Examinations for performance in teacher education programs. Educ Psychol Meas. 1993;53(2):533-9. doi: 10.1177/0013164493053002023